Entereg Documents Offer Detailed Insight Into REMS Review Process
This article was originally published in Pharmaceutical Approvals Monthly
GlaxoSmithKline's urgent communication during Entereg's second review cycle set into motion a process to resolve safety concerns that would eventually manifest in one of the strongest Risk Evaluation and Mitigation Strategy programs to date.
You may also be interested in...
The Metabolic and Endocrinologic Advisory Committee accepts LDL lowering as endpoint for homozygous hypercholesterolemia drugs, backing approval of Aegerion’s lomitapide by 13-2 and Genzyme’s mipomersen by 9-6, but hones in on the need for better surrogates for cardiovascular morbidity and mortality.
Adolor is abandoning development of Entereg (alvimopan) for chronic opioid bowel dysfunction just three months after its post-operative ileus partner, GlaxoSmithKline, returned rights for chronic indications
GSK returns rights to alvimopan in outpatient settings; partnership continues for approved hospital use.